Mesoblast share price dips amid latest class action news

The company is being taken to court by another unhappy shareholder.

| More on:
An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Key points

  • The Mesoblast share price is in the red on Thursday, slipping 1.93% to trade at $1.01
  • The dip comes amid news the company has been hit with another class action
  • Mesoblast has vowed to fight the latest allegations and noted it recently settled a similar suit in the US without admitting liability

The Mesoblast Limited (ASX: MSB) share price is slipping lower as the company is hit with another class-action lawsuit.

A shareholder is suing the biotechnology company alleging it misled the market about its remestemcel-L product.

At the time of writing, the Mesoblast share price is $1.01, 1.93% lower than its previous close.

For context, the S&P/ASX All Ordinaries Index (ASX: XAO) is currently also down 1.41%. Meanwhile, the S&P/ASX 200 Health Care Index (ASX: XHJ) is up 0.26%.

Let's take a closer look at the details.

Mesoblast facing a new class action

The Mesoblast share price is slipping amid news a class action proceeding in the Federal Court of Australia has been served on the company.

Law firm William Roberts Lawyers has brought the action against Mesoblast. The firm is representing a person who bought shares in the company between February 2018 and December 2020.

It alleges the company engaged in unlawful conduct that misled the market about remestemcel-L. 

"Mesoblast will vigorously defend against the proceeding," the company said in a statement published to the ASX.

It also noted it resolved a similar suit in the United States for $2 million without admitting liability in April. The company's insurer covered the cost of the settlement.

Mesoblast has reportedly faced multiple class actions in the US on similar allegations.

Previous actions claimed Mesoblast didn't inform investors about adverse aspects of particular remestemcel-L trials, the Australian Financial Review reported in 2020.

That reportedly prompted the FDA to demand a further controlled study of the drug before it could be given the green light to treat acute graft versus host disease in children.

And it might not be the last time the market hears news of a class action against the company.

Australian law firm Phi Finney McDonald has also been looking into a class action against Mesoblast over the past few months.

Mesoblast share price snapshot

This year has been rough on the Mesoblast share price.

The stock has tumbled nearly 28% year to date. It's also nearly 45% lower than it was this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »